AstraZeneca to Unveil its Robust Pipeline of Breast Cancer at SABCS

 AstraZeneca to Unveil its Robust Pipeline of Breast Cancer at SABCS

AstraZeneca to Unveil its Robust Pipeline of Breast Cancer at SABCS

Shots:

  • AstraZeneca will divulge new developments across BC at the 2020 SABCS. The key abstract includes data of P-ll DESTINY-Breast01 study reinforcing the efficacy seen with Enhertu in HER2+ mBC following 2+ prior anti-HER2 based regimens
  • The company will present data of P-I SERENA-1 study demonstrating the efficacy & safety of AZD9833 as a monothx. and in combination with the palbociclib in HR+, HER2- negative advanced BC
  • AstraZeneca will present RWE to understand outcomes for patients with germline BRCA mutations and treatment patterns among patients with HER2+ mBC. The company will also showcase data on the role of AI & digital pathology in measuring levels of HER2 expression in patients with BC

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Stat

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post